Antimmune is developing precision therapeutics for antibody-mediated diseases, beginning with autoimmune blistering skin diseases of which most have high relapse rates to immunosuppressants/steroids and no approved biologics. It differentiates itself through a proprietary platform that rapidly isolates and characterizes disease-causing antibodies and the cells that produce them, enabling the development of novel treatments. This technology offers greater scale, speed, cost-efficiency, and data dimensionality than competitive technologies currently in the market.